EUVIMEDEUVIMED entdecken
Open Access

First-Line Antituberculosis Drug Challenge Reactions in Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome in an HIV Endemic Setting

Mireille Porter, Rhodine Smith, Nadine Teixeira, Bukiwe Thwala, Phuti Choshi, Elizabeth J Phillips, Graeme Meintjes, Sipho Dlamini, Jonathan Grant Peter, Rannakoe J Lehloenya

The Journal of Allergy and Clinical Immunology: In Practice · 2024

DOI: 10.1016/j.jaip.2024.05.045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2024. Verfasst von Mireille Porter und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: Drug Hypersensitivity Syndrome, Antitubercular Agents, HIV Infections. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NHGRI NIH HHS, FIC NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In high HIV prevalence settings, first-line antituberculosis drug (FLTD)-associated drug reaction with eosinophilia and systemic symptoms (DRESS) poses therapeutic challenges. A sequential and additive drug challenge (SADC) of FLTDs best identifies offending drug(s), avoids unnecessary exclusions, and optimizes reinitiation of nonoffending drugs. However, SADC-associated reaction complexities limit its utility. OBJECTIVE: We aimed to describe the characteristics of patients with FLTD-associated DRESS, their treatment-limiting SADC reactions, and related outcomes. METHODS: Patients hospitalized with FLTD-associated DRESS from 2013 to 2023 in a South African tertiary hospital and enrolled (retrospectively or prospectively) in an existing registry were eligible. RESULTS: SADC was undertaken in 41 patients. Overall, 47 classifiable reactions occurred. 34/47 (72%) reactions in 29/41 (71%) patients were treatment-limiting and 12 of 41(29%) patients reinitiated FLTDs uneventfully. Fifteen single and 8 multiple drug reactors were identified. Rifampicin in 13 of 23(57%) reactors was the most common individual offender. Ethambutol was most frequently involved in multiple drug reactors. The median (interquartile range) time to a detectable reaction was 24(12-120) hours, 6 of 34(18%) being immediate (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Hypersensitivity SyndromeAntitubercular AgentsHIV InfectionsHumansMaleFemaleAdultMiddle AgedSouth AfricaEndemic DiseasesProspective StudiesRetrospective Studies

Stichwörter der Autor:innen

Drug challengeDrug reaction with eosinophilia and systemic symptoms syndromeDrug-induced hypersensitivity syndromeFirst-line antituberculosis drugsHIVMultiple drug hypersensitivityOral provocation testingTuberculosis

Substanzen

Antitubercular Agents

Autor:innen und Institutionen

  • Division of Dermatology, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
  • Division of Dermatology, Stellenbosch University, Cape Town, South Africa.
  • Division of Allergy and Clinical Immunology, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
  • Division of Allergy and Clinical Immunology, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa; Allergy and Immunology Unit, University of Cape Town Lung Institute, Cape To…
  • Center for Drug Safety and Immunology, Department of Medicine Vanderbilt University Medical Center, Nashville, Tenn; Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, WA, Australia.
  • Department of Medicine and Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Förderung

  • NIAID NIH HHS
  • NHGRI NIH HHS
  • FIC NIH HHS
  • Wellcome Trust

Zitieren

APA

Porter, M., Smith, R., Teixeira, N., Thwala, B., Choshi, P., Phillips, E. J., Meintjes, G., Dlamini, S., Peter, J. G., & Lehloenya, R. J. (2024). First-Line Antituberculosis Drug Challenge Reactions in Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome in an HIV Endemic Setting. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2024.05.045

Vancouver

Porter M, Smith R, Teixeira N, Thwala B, Choshi P, Phillips EJ, et al. First-Line Antituberculosis Drug Challenge Reactions in Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome in an HIV Endemic Setting. The Journal of Allergy and Clinical Immunology: In Practice. 2024. doi:10.1016/j.jaip.2024.05.045

BibTeX
@article{Porter2024,
  author = {Porter, Mireille and Smith, Rhodine and Teixeira, Nadine and Thwala, Bukiwe and Choshi, Phuti and Phillips, Elizabeth J and Meintjes, Graeme and Dlamini, Sipho and Peter, Jonathan Grant and Lehloenya, Rannakoe J},
  title = {First-Line Antituberculosis Drug Challenge Reactions in Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome in an HIV Endemic Setting},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2024},
  doi = {10.1016/j.jaip.2024.05.045}
}
Kostenlos starten →